Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of Anvumetostat in MTAP-deleted previously treated advanced NSCLC
jRCT2031240656Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of anvumetostat in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Amgen. Primary endpoints: Objective Response (OR) per RECIST 1.1, Objective response (OR) per RECIST 1.1 (duplicated primary description) and 5 more. Started Dec 2024; status: active, not recruiting.
02
Drugs
anvumetostat
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240656.